Nektar Therapeutics 2Q Revenues: $60 million (+110%) 2Q Loss: $63 million (loss of $27 million in 2Q2005) YTD Revenues: $89 million (+56%) YTD Loss: $96 million (loss of $53 million YTD2005) Comments: In the quarter, product sales and royalty revenue was $44 million, including three months of Exubera product sales to Pfizer, compared to $5.5 million in 2Q2005. The company’s lead product, Amphotericin B Inhalation Powder, received Orphan Drug and Fast Track designation,...